Jan. 6, 2006 -- The US Food and Drug Administration (FDA), Cangene Corporation, and Baxter Healthcare Corporation have warned healthcare professionals via letter regarding the rare risk for serious ...

THE sequence of hemoglobinuria followed by oliguria and anuria is well known. The observations reported below are especially concerned with the medical management of the anuric patient and with the ...

Acute immune intravascular hemolysis can also represent a delayed hemolytic transfusion reaction. This is a consideration in this case, because the patient received 2 units of red cells 2 weeks before ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and lethal disorder of the blood in which the body attacks and destroys red blood cells in massive amounts. This focus collection and short ...

The FDA, Cangene, and Baxter have notified healthcare professionals that cases of intravascular hemolysis (IVH) and its complications have been reported in patients treated for immune thrombocytopenic ...

Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate ...

Please provide your email address to receive an email when new articles are posted on . Ravulizumab led to maintained control of intravascular hemolysis and sustained stable hemoglobin levels ...

The patient in the case reported below received no sulfonamide. The clinical and experimental data indicate that exposure and diffuse chilling were instrumental in producing the anemia. These data are ...

Hemolysis causes a range of symptoms including fatigue, shortness of breath, and life-threatening blood clots. Inhibition of C5, a protein involved in complement system activation, is an established ...